22 unknown, 19 recruiting, 13 completed, 5 active not recruiting. 42 Phase 2, 18 Phase 1, 8 Phase 3, 7 Not applicable, 1 Phase 4.
Follow this condition Literature Review of Primary Central Nervous System Lymphoma trials Research Report on Primary Central Nervous System Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma Penpulimab, Rituximab, Methotrexate - Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma | Not applicable | Not yet recruiting | WEI XU | 58 | 2026-08-01 | 2026-08-14 |
| Methotrexate Early Toxicity Monitoring methotrexate plasmatic dosing - Primary Central Nervous System Lymphoma | Not applicable | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 50 | 2026-04-01 | 2026-02-12 |
| Rapid Diagnosis and Treatment Response Monitoring of Primary CNS Lymphoma Using CSF ctDNA Liquid Biopsy HD-MTX-based chemotherapy, BTK inhibitor - Primary Central Nervous System Lymphoma | Recruiting | Xiaohui Ren | 300 | 2026-01-01 | 2026-10-01 | |
| A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL Pirtobrutinib, Sintilimab, Rituximab, Methotrexate, Standard of Care (Investigator Selected) - PCNSL, Primary Central Nervous System Lymphoma | Phase 2 | Recruiting | Tongji Hospital | 77 | 2025-12-25 | 2026-06-02 |
| Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL Teniposide, Orelabrutinib, MTX - Primary Central Nervous System Lymphoma | Phase 2 / Phase 3 | Recruiting | Huashan Hospital | 215 | 2025-10-01 | 2026-08-19 |
| Q702 for the Treatment of Patients With Hematologic Malignancies Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration - Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma | Phase 1 | Recruiting | Mayo Clinic | 46 | 2025-08-27 | 2025-10-10 |
| A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) ibrutinib, Epcoritamab - Primary Central Nervous System Lymphoma (PCNSL), Primary Central Nervous System Lymphoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 26 | 2025-08-13 | 2026-07-14 |
| Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma Biospecimen Collection, Computed Tomography, Glofitamab - Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma | Phase 1 | Suspended | City of Hope Medical Center | 20 | 2025-07-30 | 2026-07-06 |
| Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) - Primary Central Nervous System Lymphoma | Not applicable | Recruiting | Zhejiang Cancer Hospital | 44 | 2025-02-14 | 2025-02-18 |
| Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL Pembrolizumab, Methotrexate, Temozolomide - Lymphoma, Primary Central Nervous System Lymphoma | Phase 1 | Recruiting | Dana-Farber Cancer Institute | 15 | 2024-10-18 | 2026-02-20 |
| Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL ONO-4059, Rituximab, Methotrexate - Primary Central Nervous System Lymphoma | Phase 1 | Active not recruiting | Ono Pharmaceutical Co., Ltd. | 20 | 2024-05-17 | 2026-10-06 |
| Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas Pemetrexed, Zanubrutinib, Autologous Stem Cell Transplant (ASCT) - Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma | Phase 2 | Recruiting | Baptist Health South Florida | 15 | 2024-04-25 | 2026-03-03 |
| Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response Cognitive Assessment, Obinutuzumab, Quality of Life Assessment - Primary Central Nervous System Lymphoma | Phase 2 | Recruiting | Providence Health & Services | 28 | 2024-03-13 | 2026-09-23 |
| [18F]-Fludarabine PET/MRI in Primary Central Nervous System Lymphoma PET-MRI - Primary Central Nervous System Lymphoma | Phase 1 | Completed | Assistance Publique - Hôpitaux de Paris | 10 | 2023-12-18 | 2025-08-22 |
| Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104) Tirabrutinib, Placebo - Primary Central Nervous System Lymphoma | Phase 2 | Recruiting | Kyorin University | 92 | 2023-10-06 | 2026-08-05 |
| A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL zanubrutinib 160 mg BID orally - Primary Central Nervous System Lymphoma | Not applicable | Unknown | Huai'an First People's Hospital | 30 | 2023-09-15 | 2024-06-06 |
| New-diagnosed PCNSL Treated With Methotrexate (MTX) and Orelabrutinib-based Regimen Orelabrutinib - Primary Central Nervous System Lymphoma | Completed | Huashan Hospital | 136 | 2023-08-10 | 2025-09-16 | |
| Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients R-MP and Procarbazine maintenance, R-MTX/AraC (MARTA) induction followed by consolidating HCT-ASCT - Primary Central Nervous System Lymphoma | Phase 3 | Recruiting | University Hospital Freiburg | 340 | 2023-08-09 | 2025-02-17 |
| A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) GNC-038 - Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 7 | 2023-02-10 | 2025-09-26 |
| Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma Glucarpidase, Methotrexate (MTX) - Primary Central Nervous System Lymphoma | Phase 1 | Unknown | Assistance Publique - Hôpitaux de Paris | 18 | 2022-09-15 | 2022-10-25 |
Showing 20 of 68. Sign in to see all of them.
Lymphoma (8) · Recurrence (7) · Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, Non-Hodgkin (5) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, B-Cell, Marginal Zone (3) · Neoplasms (3) · Waldenstrom Macroglobulinemia (3) · Dendritic Cell Sarcoma, Interdigitating (2) · Leukemia, Myelomonocytic, Chronic (2) · Lymphoma, Follicular (2) · Lymphoma, T-Cell, Cutaneous (2) · Multiple Myeloma (2) · Primary Myelofibrosis (2) · Blast Crisis (1)
Hemic and Lymphatic Diseases (13) · Immune System Diseases (13) · Immunoproliferative Disorders (13) · Lymphatic Diseases (13) · Lymphoproliferative Disorders (13) · Neoplasms by Histologic Type (13) · Neoplasms (12) · Disease Attributes (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Lymphoma, B-Cell (6) · Hematologic Diseases (5) · Lymphoma (5) · Blood Protein Disorders (4) · Cardiovascular Diseases (4)
Methotrexate (22) · Rituximab (21) · orelabrutinib (9) · Temozolomide (8) · Lenalidomide (5) · Cytarabine (4) · ibrutinib (4) · pembrolizumab (4) · Dexamethasone (3) · Magnetic Resonance Spectroscopy (2) · Pemetrexed (2) · Procarbazine (2) · Radiotherapy (2) · Specimen Handling (2) · obinutuzumab (2)
Assistance Publique - Hôpitaux de Paris (4) · Huashan Hospital (3) · Peking Union Medical College Hospital (3) · Second Affiliated Hospital, Zhejiang University, School of Medicine (3) · Dana-Farber Cancer Institute (2) · Memorial Sloan Kettering Cancer Center (2) · Mingzhi Zhang (2) · National Cancer Institute (NCI) (2) · Navy General Hospital, Beijing (2) · PIQUR Therapeutics AG (2) · Affiliated Hospital to Academy of Military Medical Sciences (1) · Assistance Publique Hopitaux De Marseille (1) · Baptist Health South Florida (1) · Beijing Sanbo Brain Hospital (1) · Beijing Tiantan Hospital (1)
China (28) · United States (18) · France (9) · Germany (2) · Italy (2) · Japan (2) · Taiwan (2) · Australia (1) · Austria (1) · Belgium (1) · Denmark (1) · Finland (1) · New Zealand (1) · South Korea (1) · Spain (1)
Lakshmi Nayak, MD (3) · Tong Chen (3) · Christian Grommes, MD (2) · Gerald Illerhaus, Prof (2) · Liren Qian, M.D. (2) · Agnieszka Korfel, MD (1) · Ann Woolfrey (1) · Ann-Lii Cheng, Ph.D. (1) · Augusti Alentorn, MD (1) · Carole Soussain, MD (1) · Ching-Hung Lin, M.D. (1) · Daniela Bota, MD (1)
PMID 38366824, PMID 17284616, PMID 18698002, PMID 30785830, PMID 31977002, PMID 35834762, PMID 37317993, PMID 38356447, PMID 40425940, PMID 41485126, PMID 41672977
2014 (2), P01CA018029 (1), P30CA015704 (1), P30CA033572 (1)